Tofacitinib · Regulatory label update

FDA supplemental approval: Xeljanz XR (Labeling)

U.S. Food and Drug Administration · June 30, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

This is a FDA supplemental approval action granting a labeling change for Xeljanz XR (tofacitinib citrate), approved 30 June 2026. The record documents the regulatory decision and product formulations (11 mg and 22 mg extended-release tablets) but contains no clinical trial results, efficacy data, safety findings, or comparative evidence.

What was studied

Regulatory label update.

Key findings

Safety

This is a regulatory submission record documenting approval only; it does not contain clinical trial results, efficacy endpoints, or safety data.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

FDA supplemental approval of labeling for Xeljanz XR (tofacitinib); regulatory action does not report clinical trial efficacy or safety data.

Reported figures

Quoted from the source exactly as published.

Approval date2026-06-30

Active ingredient strength 1TOFACITINIB CITRATE EQ 11MG BASE

Active ingredient strength 2TOFACITINIB CITRATE EQ 22MG BASE

Caveats

This is a regulatory submission record documenting approval only; it does not contain clinical trial results, efficacy endpoints, or safety data.
The specific labeling changes approved are not detailed in this record.
No population, sample size, or comparative data are reported.
Clinical rationale for the labeling supplement is not provided in this document.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory action record; no study design reported.

Directness

insufficient

Labeling supplement; clinical trial data not provided in this record.

Consistency

insufficient

No comparative or outcome data reported in this regulatory submission.

Risk of bias

insufficient

Regulatory approval record does not assess or report trial bias.

Sample adequacy

insufficient

No sample size or population data provided in this labeling approval.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Drugs@FDA record for application NDA208246. This is a regulatory action record, not a clinical study. Brand name: XELJANZ XR. Active ingredient: TOFACITINIB. Sponsor: PFIZER. Submission type: SUPPL (supplement). Submission class: Labeling. Approval status date: 2026-06-30. Products: XELJANZ XR, TABLET, EXTENDED RELEASE, ORAL, TOFACITINIB CITRATE EQ 11MG BASE; XELJANZ XR, TABLET, EXTENDED RELEASE, ORAL, TOFACITINIB CITRATE EQ 22MG BASE.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

TofacitinibPfizer